Psyence Biomedical Ltd. Common Shares (PBM) — Cash Flow-to-Debt Ratio

Latest as of December 2023: -0.05x

Psyence Biomedical Ltd. Common Shares (PBM) has a Cash Flow-to-Debt Ratio of -0.05x as of December 2023, meaning its operating cash flow of $-662.00 could theoretically repay 0% of its total liabilities ($12.10K) in one year. See Psyence Biomedical Ltd. Common Shares free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.

CF-to-Debt Ratio

-0.05x
Operating CF / Total Liabilities

Operating Cash Flow

$-662.00
USD

Total Liabilities

$12.10K
USD

Data as of

Dec 2023
Most recent filing

Psyence Biomedical Ltd. Common Shares Cash Flow-to-Debt Ratio (2022–2025)

Historical debt coverage capacity for Psyence Biomedical Ltd. Common Shares across 4 annual periods. For the full cash flow conversion analysis, see Psyence Biomedical Ltd. Common Shares (PBM) cash conversion ratio.

Annual Cash Flow-to-Debt Ratio for Psyence Biomedical Ltd. Common Shares (2022–2025)

Year-by-year debt coverage analysis for Psyence Biomedical Ltd. Common Shares. Check Psyence Biomedical Ltd. Common Shares (PBM) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.

Year CF-to-Debt Ratio Operating CF (USD) Total Liabilities YoY Change
2025 -6.28x $-3.73 Million $594.37K ▼ -2482.0%
2024 -0.24x $-2.95 Million $12.10 Million ▼ -568.3%
2023 -0.04x $-519.60K $14.27 Million ▲ +57.3%
2022 -0.09x $-1.40 Million $16.38 Million
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.